No abstract

No abstract

To investigates the association between the use of anticoagulation and mortality among hospitalized patients with COVID-19 in order to provide clinical insights. METHODS: An electronic search was conducted in Pubmed, Scopus, and Medrxiv (preprint articles), using the search strategy included all MeSH terms and free keywords found for "coronavirus 2019" OR "COVID-19" OR "2019-nCoV" or "SARS-CoV-2", AND "anticoagulation" OR "heparin" OR "enoxaparin" OR "apixaban" OR "rivaroxaban" between 2019 and present time without language restriction. The title, abstract, and full text of all documents captured with these search criteria were scrutinized, and those reporting the rate of anticoagulation in COVID-19 patients were included in this meta-analysis. The reference list of these identified studies was also analyzed (forward and backward citation tracking) for detection gother potential eligible articles. A meta-analysis was performed with Comprehensive Meta-Analysis software (version 3.3.070) in accordance with the PRISMA guidelines.

To understand the characteristics, comorbid conditions, and clinical outcome of patients hospitalized with coronavirus disease 2019 (COVID-19) in the US. METHODS: This analysis included data from 7 acute care hospitals in the Mount Sinai Health System, which serves approximately 3.5 million patients in the New York metropolitan area. We included all consecutively hospitalized adults between March 1st to May 10th, 2020, who had a positive polymerase-chain-reaction testing (RT-PCR) for SARS-CoV-2 infection by nasopharyngeal or oropharyngeal swab and who had a completed hospital course (discharged alive or died) at time of analysis, May 15th, 2020. Initial testing for SARS-CoV-2 was conducted by the New York State Department of Health until March 15, 2020, when internal testing was available at the Mount Sinai laboratory. Patients who died or who were transferred to another facility within 24 hours after hospital admission were excluded from the analysis. The study used de-identified data from the Mount Sinai Data Warehouse (MSDW)-"COVID-19 Project". The Mount Sinai COVID-19 Clinical Research Protocol Review Committee approved this study and the institutional review board of Icahn School of Medicine at Mount Sinai exempted the research project from approval as it is a retrospective review of already collected, de-identified data.

Sleep Apnea is known to be associated with increased cardiovascular morbidity and mortality. Positive airway pressure (PAP) provides symptomatic relief, whether delivered continuously (CPAP) or as adaptive servo-ventilation (ASV). However, it is not clear whether treatment with PAP reduces cardiovascular risk. METHODS: Randomized clinical trials (RCT) that evaluated the treatment of sleep apnea with usual care (UC) plus PAP versus UC alone, and reported cardiovascular (CV) outcomes were identified via Pubmed, EMBASE, and CENTRAL. Data were combined using a random-effects meta-analysis model for each of the following outcomes: all-cause mortality, CV mortality, noncardiovascular mortality, myocardial infarction (MI), stroke, hospitalization for heart failure (HF), hospitalization for unstable angina (UA), and a subgroup analysis of major adverse cardiovascular events (CV mortality, MI, and stroke) according to adherence to PAP (<4 vs $4 h/d).